.png)
The adjunctive use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) as an addition to insulin is increasingly viewed as a method for addressing the rising prevalence of obesity in type 1 diabetes (T1D). Current GLP-1 RA drugs, such as semaglutide and the dual glucagon-insulinotropic peptide (GIP)/GLP-1 tirzepatide...
Dsn.sebani Ds.tanjangrono RT 04 RW 01 Mojokerto-Jawa Timur
+6281993868686
lita@gdrive.or.id
Copyright © 2023 saktinews. All Rights Reserved
